Back to News
Market Impact: 0.4
MiMedx Group, Inc. Reports Third Quarter 2026 Results and $25 million Patent License Agreement
Source: Nasdaq
Corporate EarningsCompany FundamentalsHealthcare & Biotech
MiMedx Group reported third-quarter 2026 net sales of $62 million, down 45% from $114 million in the year-earlier quarter. Surgical product sales increased 9% year over year, partially offsetting the overall decline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.55
Ticker Sentiment
MDXG-0.70
More News
- What MiMedx Group (MDXG) Said on Its Q3 Earnings Call
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- SK Hynix says the memory-chip shortage will last until 2030—and more than half its production is booked for the next two years
- China’s tech darlings are losing their shine. Here’s what’s behind the sell-off
- GE Vernova shares slip despite a beat-and-raise. What the sellers are getting wrong
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- Weekly Update: Sector Analysis, Improvements on Research Data, and Performance Enhancements
- How to Automate Equity Research Workflows: A Control-First Guide